230 related articles for article (PubMed ID: 27172935)
1. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
[TBL] [Abstract][Full Text] [Related]
2. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
3. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
4. The impact of teriparatide adherence and persistence on fracture outcomes.
Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
[TBL] [Abstract][Full Text] [Related]
5. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS).
Sato M; Tsujimoto M; Kajimoto K; Uetake H; Shimoda H; Fujiwara S
Arch Osteoporos; 2018 Jul; 13(1):74. PubMed ID: 29978364
[TBL] [Abstract][Full Text] [Related]
6. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
[TBL] [Abstract][Full Text] [Related]
7. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
9. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
Krege JH; Wan X
Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
[TBL] [Abstract][Full Text] [Related]
11. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
[TBL] [Abstract][Full Text] [Related]
13. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
15. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
16. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
Foster SA; Foley KA; Meadows ES; Johnston JA; Wang SS; Pohl GM; Long SR
Osteoporos Int; 2011 Feb; 22(2):551-7. PubMed ID: 20798929
[TBL] [Abstract][Full Text] [Related]
17. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.
Kyvernitakis I; Kostev K; Kurth A; Albert US; Hadji P
Osteoporos Int; 2014 Dec; 25(12):2721-8. PubMed ID: 25011986
[TBL] [Abstract][Full Text] [Related]
18. Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.
Boytsov N; Zhang X; Sugihara T; Taylor K; Swindle R
Curr Med Res Opin; 2015; 31(9):1665-75. PubMed ID: 26121328
[TBL] [Abstract][Full Text] [Related]
19. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
